Table 4 Randomized prospective trials of neoadjuvant therapy plus surgery versus surgery alone for esophageal adenocarcinoma
From: Developments in esophageal surgery for adenocarcinoma: a comparison of two decades
author/year | n | survival: C + S | survival: S | p-value |
|---|---|---|---|---|
Kelsen/1998 (25) | 440 (54% ADC, 46% SCC) | 14.9 mo 2 yr: 35% | 16.1 mo 2 yr: 37% | n.s. |
MRC/2002 (26) | 802 (66% ADC, 31% SCC) | 16.8 mo 2 yr: 43% | 13.3 mo 2 yr: 34% | 0.004* |
| Â | Â | survival: CR + S | survival: S | Â |
Walsh/1996 (27) | 58 (100% ADC) | 16 mo 3 yr: 32% | 11 mo 3 yr: 6% | 0.01* |
Urba/2001 (28) | 100 (75% ADC, 25% SCC) | 16.9 mo 3 yr: 30% | 17.9 mo 3 yr: 16% | n.s. |
Burmeister/2002 (29) | 256 (61.7% ADC, 37.1% SCC) | 21.7 mo 3 yr: 38% | 18.5 mo 3 yr: 31% | n.s. |
Junginger 2006 | 175 ADC | 17.2 mo 3 yr: 33% | Â | Â |